Previous Close | 2.7600 |
Open | 2.7600 |
Bid | 1.9500 x N/A |
Ask | 2.0200 x N/A |
Day's Range | 2.7600 - 2.7600 |
52 Week Range | 1.7100 - 2.8800 |
Volume | |
Avg. Volume | 10 |
Market Cap | 71.576M |
Beta (5Y Monthly) | -0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
AUSTIN, Texas, May 15, 2024--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisoning (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2024, and recent updates.
AUSTIN, Texas, February 13, 2024--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
AUSTIN, Texas, November 14, 2023--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates